Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO

Fulcrum Therapeutics, a Cambridge, MA, startup run by the former CEO of Epizyme, has closed an $80 million Series B round that lays the groundwork for a likely IPO next year, its CEO says.